***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed three more positions; two for gains and one for a loss.

ASTEX PHARMACEUTICALS (12/5/10). Closed position 3/8/13 at $4.56 for a 72% GAIN.

MERU NETWORKS (8/20/12). Closed position 3/6/13 at $5.32 for a 62% GAIN.

CD INT’L (4/5/10). Closed position at 9 cents for a 94% LOSS.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Since the last Newsletter, we closed two more positions; one for a gain and the other for a loss.

ENERGY RECOVERY (5/5/11). Closed position 2/25/13 at $4.83 for a 57% GAIN.

AMERICAN CARESOURCE (4/20/10). Closed position 2/25/13 at $1.90 for a 67% LOSS.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Since the last Newsletter, we closed three positions; two for gains and one for a loss.

GALACTIN THERAPEUTICS (12/20/12). Closed position 2/8/13 at $3.00 for a 60% GAIN.

PROPHASE LABS (10/5/10). Closed position 2/4/13 at $1.78 for a 54% GAIN.

GREAT BASIN GOLD (1/5/11). Closed position 2/5/13 at 9 cents for a 97% LOSS.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed one position for a gain.

ACELRX PHARMACEUTICALS (11/20/12). Closed position 1/22/13 at $5.80 for a 55% GAIN.

AcelRx Pharmaceuticals had been inching up since for picked it a few months back, and, for unknown reasons, the stock pierced our 50%-plus ceiling, and we’ll take the gain.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

The new year is off to a decent start for the markets, thanks to an 11^th-hour tax deal where the congressional Republicans caved. Some of their reasoning was fear that the markets would see a huge sell off, if they failed to act. Who would have cared about the sell off? Markets go up and markets go down. If they had tackled the spending issues right then, when they had some great leverage, they probably would have gotten much of the spending cuts they wanted, and the markets would be on a major tear, right now. So, what do they do? They drag the nonsense out even more. Does the GOP really think that they will get any real spending cuts, now that they trashed their real leverage? Oh sure, they think the debt ceiling clock is on their side, but that strategy failed in the mid-nineties and we suspect it will fail, again.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

To be succinct, 2012 was not a banner year for us. It wasn’t a bad year, but it fell short of what we expect from ourselves. During 2012, we closed 52 positions; 36 for gains and 16 for losses, if we count correctly. In previous years, it seems we have had more gains and fewer losses. The one bugaboo has been that for the last several years there has been a nice rally in big and mid-cap stocks while small caps, though not withering, have not kept the same pace. We feel that this has been due to the dominance of mutual funds, hedge funds, and ETFs, and other similar financial instruments, which have had little room for small stocks in their portfolio.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed three positions; one for a gain and two for losses.

BG MEDICINE (12/5/12). Closed position 12/11/12 at $3.30 for a 129% GAIN.

COMBIMATRIX (8/20/10). Closed position 12/11/12 at $12 for a 57% LOSS.
(price reflects 1 for 10 reverse split)

YM BIOSCIENCES (11/5/06). Closed position 12/12/12 at $2.90 for a 3% LOSS.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter we closed only one position for a very nice gain.

BIOMIMETRIC THERAPEUTICS (9/20/11). Closed position 11/19/12 at $7.34 for a 98% GAIN.

This seems to be happening more than usual as a big company swoops in on one of our Current Portfolio picks and its fun time! It was nice to get almost a 100% gain as Wright Medical acquired BioMimetric Therapeutics.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed four positions; two for gains and two others for losses.

HANSEN MEDICAL (9/20/12). Closed position 11/1/12 at $2.50 for a 60% GAIN.

SPRINT NEXTEL (1/5/11). Closed position 11/6/12 at $5.80 for a 36% GAIN.

A123 SYSTEMS (1/20/12). Closed position 11/5/12 at 13 cents for a 93% LOSS.

SOMAXON PHARMA (7/5/11). Closed position 11/2/12 at $1.67 for an 89% LOSS.
(price reflects reverse stock split)

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Between the market sell off and Hurricane Sandy, October was a lousy month. The market downturn, once again, battered our Current Portfolio, and, as many of you know, small stocks get banged up even more than large and mid-cap stocks during such periods. What will November bring for the markets? Who knows? Will Romney or Obama be better suited to fix the economy and prevent the Fiscal Cliff? A case can be made for both gentlemen, although Romney seems to have a better background for such challenges. Will Europe keep it together? Will the Fed’s QE Forever policy be ignored in favor of fundamentals? As shocking as this may seem, many market pros, such as fund managers, would prefer keeping Obama and the status quo of easy money.

(more…)